A New Chapter in Gene Therapy

        Recent advances in gene editing are turning what once seemed like science fiction into real treatments. One striking example is a personalized therapy developed for a baby born with a rare metabolic disorder. Researchers at Children's Hospital of Philadelphia and Penn Medicine used a base-editing version of the CRISPR-Cas9 system to correct a mutation in the CPS1 gene of a child who suffered from carbamoyl phosphate synthetase 1 deficiency. Within months of receiving the therapy, the child was able to tolerate increased protein in his diet and required fewer nitrogen-scavenging medications.

        This breakthrough shows the feasibility of tailored gene-editing for ultra rare diseases, where traditional drug development isn't practical. However, as discussed in Innovative Genomics Institute's review, the case raises ethical questions about cost, accessibility, and equity in access to gene therapy.  

FDA and Approval for Gene Therapy for Rare Diseases

 The FDA, under Commissioner Marty Makary, has proposed a streamlined regulatory pathway to accelerate approval of gene therapies for rare diseases. This initiative addresses a key limitation in the current framework: the impracticality of conducting large-scale, placebo-controlled trials in small patient populations. This allows approval based on a therapy’s plausible biological mechanism—paired with rigorous post-market confirmatory studies—the FDA aims to reduce development timelines and lower barriers to innovation, without compromising scientific integrity.

This policy shift has already caused vibrations through the biotech industry, with companies like Sarepta Therapeutics and Beam Therapeutics experiencing booms in the stock market. It reflects a growing recognition that the traditional ways of approval must evolve to keep pace with advances in precision medicine. For patients with rare and often life-limiting conditions, the proposed pathway offers renewed hope for earlier access to transformative, potentially curative treatments

My Opinion: The current administration has made some questionable decisions, but this step is helpful towards finding better ways to treat patients with rare diseases. It's best to see it through and hope it does not have a list of negative effects. Innovation is great when it's needed, but when it's not you are just helping something that doesn't need help. 

Sources:

 Sarepta Therapeutics, Genetics Stocks Rise On New FDA Commissioner's Views. Here's Why. | Investor's Business Daily

Trump’s FDA Sends a Bullish Signal to Biotech

FDA’s Makary floats new approval pathway for rare disease drugs

Irregular Prenatal Test Results Found to Indicate Cancers

A study published by The New England Journal of Medicine found that in a test meant to screen for fetal chromosomal abnormalities, individuals receiving unusual results were found to have specific types of cancer. This unusual identification is peculiar most notably as the individuals involved in the use of these prenatal tests are typically young, so identifying cancers within that age range at all is very uncommon. Although these rare, abnormal results are exceedingly infrequent, within the group of women who received these specific results nearly 50% were currently affected by (primarily) Lymphoma Colon, or Breast cancer, among others. Typically these unusual and “indecipherable” results occur in around one out of over 8000 tests performed. 

Studies such as these that discover utility associated with previously nonsensical data sets are always exceedingly intriguing. Not only does a functional discovery for erroneous data resolve the irregularities found with certain tests, which may previously have been considered a factor of inaccuracy, but this also provides alternative methods to use specific tests already manufactured on a significant scale, making modification and production of alternative test-types a viable and simple process.

Links:

https://www.science.org/content/article/unusual-genetic-results-prenatal-tests-can-also-flag-cancers-mom

https://www.nih.gov/news-events/news-releases/abnormal-prenatal-blood-test-results-could-indicate-hidden-maternal-cancers#:~:text=Researchers%20at%20the%20National%20Institutes,chromosomal%20disorders%20in%20the%20fetus.

UCLA Creates New Drug-Genetic Effectiveness Prediction Framework

UCLA has created a new method of prediction hoping to better anticipate the relative efficacy of certain prescription medications, as well as reducing their side effects. By using the submitted genetic data from approximately 342,000 UK individuals, researchers anticipate they can better predict the effectiveness of four specific medications involved in the study, Satins, Metformin, Warfarin, and Methotrexate. These medications are the beginning of larger scope studies that will involve more medications in increasingly diverse roles, though the study first must conclusively identify correlative/causative links and methods of management prior to instilling further diverse medication.

In my opinion, this study seems to be exceedingly broad in its scope and not currently an effective method of regulating and anticipating the use of certain common prescription drugs. Medications used today are employed based on their known effectiveness related to large populations regardless of their genetic identity. To effectively employ these techniques, genetic data must be gathered either prior or concurrently with treatment, which might slow down the dispensary of necessary medication when broadly effective drugs are currently available. When genetic information and resources become more viable and readily attainable in a medicinal setting for less-than exclusively genetically related ailments, this study might become more relevant. 

Links: 

https://www.news-medical.net/news/20241205/New-framework-enhances-genetic-prediction-of-drug-response-and-side-effects.aspx

https://www.uclahealth.org/news/release/genetic-data-biobanks-may-help-improve-prediction

The Axolotl's Superpower: Tissue Regeneration!

    This article discusses the sequencing of the axolotl genome, and how it may be significant in regards to human health/medical treatments. Axolotls are neotenic- in other words, they never reach "full maturity". This is how they keep their gills and continue to live underwater. They also hold the title for the largest genome ever fully sequenced. Scientists are particularly interested in researching axolotls for their incredible ability to regenerate lost tissues- even having the capability to regrow their spinal cords, and parts of their brains! Scientists may be able to learn from this ability and translate it into the medical field. Since axolotls have been used as model organisms, health-related events observed in them, such as heart problems, can be studied, and then used in respect to human health-related problems.

    I find this article to be incredibly interesting. The concept of utilizing the information axolotls provide regarding regeneration in a medical sense for humans is groundbreaking. I can only imagine the different manners in which it could be used to better our medical treatments- such as use on burn victims or use in combating degenerative diseases. It makes me wonder just how far we can push the bounds of this regenerative ability- I know we as humans will not be able to regrow entire limbs, but to what extent will we be able to practice this ability in the medical field? 

New study looks to biological enzymes as source of hydrogen fuel

Links:
Article : https://www.sciencedaily.com/releases/2019/11/191125120936.htm
Related Article: https://www.chemeurope.com/en/news/1163900/biological-enzymes-as-source-of-hydrogen-fuel.html

Biological enzymes, called hydrogenases, are nature's machinery for making and burning hydrogen gas. These enzymes come in two varieties, iron-iron and nickel-iron -- named for the elements responsible for driving the chemical reactions. The new study focuses on the iron-iron variety because it does the job faster, the researchers said.

Research from the University of Illinois and the University of California, Davis has chemists one step closer to recreating nature's most efficient machinery for generating hydrogen gas. This new development may help clear the path for the hydrogen fuel industry to move into a larger role in the global push toward more environmentally friendly energy sources.


This was an interesting article to read. Currently, hydrogen gas is produced using a very complex industrial process that limits its attractiveness to the green fuel market, the researchers said. In response, scientists are looking toward biologically synthesized hydrogen, which is far more efficient than the current human-made process, said chemistry professor and study co-author Thomas Rauchfuss.